JP2001520537A - 医薬品と核酸の骨格筋への導入方法 - Google Patents
医薬品と核酸の骨格筋への導入方法Info
- Publication number
- JP2001520537A JP2001520537A JP54134898A JP54134898A JP2001520537A JP 2001520537 A JP2001520537 A JP 2001520537A JP 54134898 A JP54134898 A JP 54134898A JP 54134898 A JP54134898 A JP 54134898A JP 2001520537 A JP2001520537 A JP 2001520537A
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- nucleic acid
- electric field
- bipolar pulse
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/205—Applying electric currents by contact electrodes continuous direct currents for promoting a biological process
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Electrotherapy Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. in vivoで、哺乳動物の骨格筋にある分子を送達する方法であって、 哺乳動物の骨格筋内に該分子を注射するステップと、 電極を通って移動する電流が注射部位を通過するように注射部位の近くに電極 の位置決めするステップと、 25V/cm〜200V/cmの電界強度を有する電流によって筋肉を電気的に刺激するス テップと を含んでなる分子送達方法。 2. 前記電気的刺激が単一の方形二極性パルスの形態で与えられることを特 徴とする請求項1に記載の分子送達方法。 3. 前記二極性パルスが約50μs〜5000μsの間に持続時間を有することを特 徴とする請求項2に記載の分子送達方法。 4. 前記電気的刺激が約2〜30,000にある方形二極性パルスの形態でデリバリ ーされることを特徴とする請求項1に記載の分子送達方法。 5. 前記二極性パルスが約10ms〜12,000msの間に合計持続時間を有すること を特徴とする請求項4に記載の分子送達方法。 6. 前記二極性パルスが少なくとも2列(トレイン)の形態で与えられるこ とを特徴とする請求項5に記載の分子送達方法。 7. 前記電気的刺激の周波数が約0.5Hz〜1000Hzにあることを特徴とする請求 項6に記載の分子送達方法。 8. 前記分子は核酸であって、前記核酸が、前記筋細胞において、前記核酸 がコードするタンパク質の発現を指示するプロモーターに、作用可能に結合され ていることを特徴とする請求項1に記載の分子送達方法。 9. in vivoで、核酸を前記哺乳動物の骨格筋内に形質転移することによって 哺乳動物を遺伝子的に免疫化する方法であって、 前記筋肉の中で、前記核酸がコードするタンパク質の発現を指示するプロモー ターに、作用可能に結合されている核酸を哺乳動物の骨格筋に注射するステップ と、 電極の中を移動する電流が、前記核酸注射部位を通過するように前記核酸注射 部位の近くに電極の位置決めするステップと、 約25V/cm〜200V/cmの電界強度を有する電流で筋肉を刺激するステップとを含 んでなる方法。 10. 前記電気的刺激が単一の方形二極性パルスの形態で与えられることを特 徴とする請求項9に記載の方法。 11. 前記二極性パルスが約50μs〜5000μsの間に持続時間を有することを特 徴とする請求項10に記載の方法。 12. 前記電気的刺激が約2〜30,000にある方形二極性パルスの形態で与えら れることを特徴とする請求項9に記載の方法。 13. 前記二極性パルスのパルス持続時間の合計が、約10ms〜12,000msの間に あることを特徴とする請求項12に記載の方法。 14. 前記二極性パルスが少なくとも2列の形態で与えられることを特徴とす る請求項13に記載の方法。 15. 前記電気的刺激の周波数が、約0.5Hz〜100Hzの間にあることを特徴とす る請求項14に記載の方法。 16. 哺乳動物においてタンパク質を全身に送達方法であって、 前記筋肉において、前記核酸がコードするタンパク質の発現を指示するプロモ ーターに、作用可能に結合されている核酸を哺乳動物の筋肉に注射するステップ と、 電極の中を移動する電流が前記核酸注射部位を通過するように前記核酸注射部 位の近くに電極の位置決めするステップと、 25V/cm〜200V/cmの電界強度を有する電流によって筋肉を刺激するステップと を含んでなる方法。 17. 前記電気的刺激が、単一の方形二極性パルスの形態で与えられることを 特徴とする請求項16に記載の方法。 18. 前記二極性パルスが、約50μs〜5000μsの間の持続時間を有することを 特徴とする請求項17に記載の方法。 19. 前記電気的刺激が、約2〜30,000の間にある方形二極性パルスの形態で 与えられることを特徴とする請求項18に記載の方法。 20. 前記二極性パルスのパルス持続時間の合計が、約10ms〜12,000msの間に あることを特徴とする請求項19に記載の方法。 21. 前記二極性パルスが少なくとも2列の形態で与えられることを特徴とす る請求項20に記載の方法。 22. 前記電気的刺激の周波数が、約0.5Hz〜1000Hzの間にあることを特徴と する請求項21に記載の方法。 23. a) 哺乳動物の骨格筋内に医薬品を注射することと、 b) 電極の中を移動する電流が注射部位を通過するように注射部位の近くに電 極の位置決めすることと、 c) 25V/cm〜200V/cmの間にある電界強度を有する電流により筋肉を電気的に 刺激することと によって、in vivoで、骨格筋への投与から成る治療において使用される医薬品 として製造される薬物の使用。 24. 前記電気的刺激が単一の方形二極性パルスの形態で与えられることを特 徴とする請求項23に記載されている薬物の使用。 25. 前記二極性パルスが、約50μs〜5000μsの間の持続時間を有することを 特徴とする請求項23または請求項24に記載されている薬物の使用。 26. 前記電気的刺激が、約2〜30,000の間にある方形二極性パルスの形態で デリバリーされることを特徴とする請求項23〜25のいずれかに記載されている薬 物の使用。 27. 前記二極性パルスが、約10ms〜12,000msの間に合計持続時間を有するこ とを特徴とする請求項23〜26のいずれかに記載されている薬物の使用。 28. 前記二極性パルスが少なくとも2列の形態で与えられることを特徴とす る請求項23〜27のいずれかに記載されている薬物の使用。 29. 前記電気的刺激の周波数が、約0.5Hz〜1000Hzの間にあることを特徴と する請求項23〜28のいずれかに記載されている薬物の使用。 30. 前記薬物が核酸から成り、前記核酸は、前記筋細胞において前記核酸が コードするタンパク質の発現を指示するプロモーターに、作用可能に結合されて いることを特徴とする請求項23〜29のいずれかに記載されている薬物の使用。 31. 前記薬物が単鎖核酸より成ることを特徴とする請求項23〜29のいずれか に記載されている薬物の使用。 32. 薬物が検出可能な標識を有することを特徴とする請求項23〜31のいずれ かに記載されている薬物の使用。 33. 医薬品あるいは治療用薬物の送達に感受性のある細胞組織を作成するた めの装置であって、 a)25V/cm〜200V/cmの電界強度を備えた電界をデリバリーすることができる電 圧制御装置と、 b)哺乳動物の身体部分の周囲に配置されるのに適し、また該身体部分に電界 を提供することができる電極と を含んでなる電圧制御装置。 34. 電界が段階を追ってあるいはパルス発生の方法で提供されることを特徴 とする請求項33に記載されている装置。 35. 電界が0.5〜1000Hzの範囲内にある周波数を提供されることを特徴とす る請求項34に記載されている装置。 36. 電界が単一の方形二極性パルスの形態で与えられることを特徴とする請 求項33〜35のいずれかに記載されている装置。 37. 電界が50〜5000μsの持続時間を有する二極性パルスとして与えられる ことを特徴とする請求項36に記載されている装置。 38. 電界が好ましくは2〜30,000方形二極性パルスといった複数のパルスの 形態で与えられることを特徴とする請求項33〜35のいずれかに記載されている装 置。 39. 方形二極性パルスの持続時間が10ms〜12,000msの間にあることを特徴と する請求項38に記載されている装置。 40. 方形二極性パルスが少なくとも2列の形態で与えられることを特徴とす る請求項39に記載されている装置。 41. 細胞組織に対して医薬品あるいは治療用薬物を送達するためのものであ ることを特徴とする請求項33〜40のいずれかに記載されている装置の使用。 42. 細胞組織が骨格筋組織であることを特徴とする請求項41に記載されてい る装置の使用。 43. 細胞組織が哺乳動物の骨格筋細胞組織であることを特徴とする請求項41 あるい42に記載されている装置の使用。 44. 医薬品あるいは治療用薬物が核酸分子であることを特徴とする請求項41 〜43のいずれかに記載されている装置の使用。 45. 核酸分子が、筋細胞内において核酸がコードするタンパク質の発現を指 示するプロモーターに、作用可能に結合されていることを特徴とする請求項44に 記載されている装置の使用。 46. 核酸が単鎖核酸であることを特徴とする請求項44に記載されている装 置の使用。 47.電界が、筋線維をおおよそ横切るその電界線によって位置決めされること を特徴とする請求項41〜46のいずれかに記載されている装置の使用。 48. 細胞組織の刺激が、医薬品あるいは治療用薬物の細胞組織への注射に関 連して行われることを特徴とする請求項41〜47のいずれかに記載されている装置 の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4259497P | 1997-04-03 | 1997-04-03 | |
US60/042,594 | 1997-04-03 | ||
PCT/IB1998/000487 WO1998043702A2 (en) | 1997-04-03 | 1998-04-03 | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005253462A Division JP2006061701A (ja) | 1997-04-03 | 2005-09-01 | 医薬品と核酸の骨格筋への導入方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001520537A true JP2001520537A (ja) | 2001-10-30 |
Family
ID=21922760
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54134898A Pending JP2001520537A (ja) | 1997-04-03 | 1998-04-03 | 医薬品と核酸の骨格筋への導入方法 |
JP2005253462A Pending JP2006061701A (ja) | 1997-04-03 | 2005-09-01 | 医薬品と核酸の骨格筋への導入方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005253462A Pending JP2006061701A (ja) | 1997-04-03 | 2005-09-01 | 医薬品と核酸の骨格筋への導入方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6110161A (ja) |
EP (1) | EP1023107B1 (ja) |
JP (2) | JP2001520537A (ja) |
KR (1) | KR100427786B1 (ja) |
CN (1) | CN1198665C (ja) |
AT (1) | ATE337794T1 (ja) |
AU (1) | AU733628B2 (ja) |
CA (1) | CA2285056C (ja) |
DE (1) | DE69835761T2 (ja) |
DK (1) | DK1023107T3 (ja) |
EA (1) | EA002087B1 (ja) |
ES (1) | ES2273408T3 (ja) |
IL (1) | IL132103A0 (ja) |
NO (1) | NO327806B1 (ja) |
NZ (1) | NZ337853A (ja) |
WO (1) | WO1998043702A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507984A (ja) * | 1997-06-30 | 2002-03-12 | ローヌ−プーラン・ロレ・エス・アー | 多細胞化真核生物細胞に核酸を導入する改良法およびその組合せ |
JP2009195756A (ja) * | 2002-04-05 | 2009-09-03 | Ichor Medical Systems Inc | 治療薬を送達する方法及び装置 |
US9364664B2 (en) | 2004-03-08 | 2016-06-14 | Ichor Medical Systems, Inc. | Apparatus for electrically mediated delivery of therapeutic agents |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
IL133710A0 (en) | 1997-06-30 | 2001-04-30 | Rhone Poulence Rorer S A | Improved method for transferring nucleic acid into the striped muscle and combination thereof |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
WO2000002621A1 (en) | 1998-07-13 | 2000-01-20 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US7922709B2 (en) | 1998-07-13 | 2011-04-12 | Genetronics, Inc. | Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation |
WO2000045823A1 (en) * | 1999-02-08 | 2000-08-10 | Chiron Corporation | Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo |
US6593130B1 (en) * | 1999-04-16 | 2003-07-15 | The Regents Of The University Of California | Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy |
EP1309904A4 (en) * | 2000-03-03 | 2006-03-29 | Valentis Inc | IMPROVED POLOXAMER AND POLYOAMINE COMPOUNDS FOR NUCLEINE SUCTION INTRODUCTION |
AU6475901A (en) | 2000-05-22 | 2001-12-03 | Merck And Company Inc | System and method for assessing the performance of a pharmaceutical agent delivery system |
US6733485B1 (en) | 2001-05-25 | 2004-05-11 | Advanced Bionics Corporation | Microstimulator-based electrochemotherapy methods and systems |
US20040204669A1 (en) * | 2001-07-05 | 2004-10-14 | Hofmann Gunter A. | Apparatus for electroporation mediated delivery for drugs and genes |
US7713740B2 (en) * | 2001-08-24 | 2010-05-11 | University Of South Florida | Method of using electric fields to facilitate the entry of molecules into cells in vivo |
EP2172552A3 (en) | 2001-10-11 | 2010-07-21 | Merck Sharp & Dohme Corp. | Recombinant nucleic acids comprising regions of AD6 |
AU2002337840B2 (en) | 2001-10-11 | 2007-08-09 | Msd Italia S.R.L. | Hepatitis C virus vaccine |
WO2003039344A2 (en) * | 2001-11-08 | 2003-05-15 | The Regents Of The University Of California | Methods and compositions for correction of cardiac conduction disturbances |
CA2470322A1 (en) * | 2001-12-14 | 2003-06-26 | Genetronics, Inc. | Methods for particle-assisted polynucleotide immunization using a pulsed electric field |
AU2003201093A1 (en) * | 2002-01-18 | 2003-07-30 | Inovio As | Bispecific antibody dna constructs for intramuscular administration |
US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US20050154434A1 (en) | 2002-03-07 | 2005-07-14 | Adam Simon | Clinical syringe with electrical stimulation aspects |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
ATE402732T1 (de) | 2002-04-16 | 2008-08-15 | Cyto Pulse Sciences Inc | Verfahren zur behandlung von biologischen materialien mit übersetzenden elektrischen feldern und elektroden-polaritäts-umkehr |
US20040106896A1 (en) * | 2002-11-29 | 2004-06-03 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
WO2006102684A2 (en) | 2005-03-19 | 2006-09-28 | The Regents Of The University Of California | Ultra low strength electric field network-mediated ex vivo gene, protein and drug delivery in cells |
ES2948791T3 (es) | 2005-06-17 | 2023-09-19 | Msd Italia Srl | Vacuna de ácido nucleico contra el virus de la hepatitis C |
CA2640286C (en) * | 2006-02-13 | 2018-01-02 | Oncolytics Biotech Inc. | Use of local immune suppression to enhance oncolytic viral therapy |
JP5646851B2 (ja) | 2006-11-17 | 2014-12-24 | ジェネトロニクス,インコーポレイティド | エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法 |
ES2399088T3 (es) | 2007-11-01 | 2013-03-25 | Perseid Therapeutics Llc | Polipéptidos y ácidos nucleicos inmunosupresores |
EP2265715B1 (en) | 2008-04-04 | 2016-12-28 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same |
AU2009231559B2 (en) * | 2008-04-04 | 2015-10-22 | The Trustees Of The University Of Pennsylvania | Consensus sequences of Chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
EP2147697A1 (en) | 2008-07-21 | 2010-01-27 | Centre National De La Recherche Scientifique-CNRS | Process and device for applying electric fields into conductive material |
EP2156860A1 (en) | 2008-08-20 | 2010-02-24 | Centre National De La Recherche Scientifique-CNRS | Method for producing insulated electrodes for applying electric fields into conductive material |
US20100298697A1 (en) * | 2009-05-19 | 2010-11-25 | Medtronic, Inc. | Method and devices for improved efficiency of rna delivery to cells |
US8207138B2 (en) | 2009-05-19 | 2012-06-26 | Medtronic, Inc. | Methods and devices for improved efficiency of RNA delivery to cells |
KR20120093163A (ko) | 2009-09-14 | 2012-08-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Il-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법 |
CN106987595B (zh) | 2009-11-02 | 2021-07-06 | 宾夕法尼亚大学托管会 | 口蹄疫病毒病毒(fmdv)共有蛋白质、其编码序列及由其制备的疫苗 |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
AU2011213559B2 (en) | 2010-02-08 | 2015-05-07 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same |
WO2012047679A2 (en) | 2010-09-27 | 2012-04-12 | The Trustees Of The University Of Pennsylvania | Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria |
BR112013011705B1 (pt) | 2010-11-12 | 2022-04-05 | The Trustees Of The University Of Pennsylvania | Antígenos de próstata de consenso, molécula de ácido nucleico quecodifica os mesmos e vacina e usos compreendendo os mesmos |
AU2012212264B2 (en) | 2011-01-31 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
PT2672992T (pt) | 2011-02-11 | 2020-07-27 | Univ Pennsylvania | Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma |
CN103717249B (zh) | 2011-06-15 | 2017-03-22 | 克洛恩泰克制药股份公司 | 注射针和装置 |
EP2731628B1 (en) | 2011-07-11 | 2019-09-04 | Inovio Pharmaceuticals, Inc. | Dna vaccine against lassa virus |
WO2013090294A1 (en) | 2011-12-12 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections |
CN104245719B (zh) | 2011-12-12 | 2016-09-14 | 宾夕法尼亚大学托管会 | 包含改进的il-12基因构建体的组合物和疫苗、免疫治疗剂及其使用方法 |
US10040828B2 (en) | 2012-04-10 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
US9597388B2 (en) | 2012-04-12 | 2017-03-21 | The Trustees Of The University Of Pennslyvania | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
DE102012013534B3 (de) | 2012-07-05 | 2013-09-19 | Tobias Sokolowski | Vorrichtung für repetitive Nervenstimulation zum Abbau von Fettgewebe mittels induktiver Magnetfelder |
WO2014064534A2 (en) | 2012-10-05 | 2014-05-01 | Chrontech Pharma Ab | Injection needle, device, immunogenic compositions and method of use |
WO2014093886A1 (en) | 2012-12-13 | 2014-06-19 | The Trustees Of The University Of Pennsylvania | Wt1 vaccine |
ES2817903T3 (es) | 2013-03-15 | 2021-04-08 | Univ Pennsylvania | Proteínas de consenso del virus de la Fiebre Aftosa (VFA), secuencias codificantes y vacunas preparadas a partir de las mismas |
CN114225019A (zh) | 2013-03-15 | 2022-03-25 | 宾夕法尼亚大学理事会 | 癌疫苗及使用其的治疗方法 |
JP6692294B2 (ja) | 2013-07-31 | 2020-05-13 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーBioVentures, LLC | 腫瘍関連糖鎖抗原を標的として癌を治療及び予防するための組成物及び方法 |
EP3080159A4 (en) | 2013-12-13 | 2017-08-02 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
BR112017011556A2 (pt) | 2014-12-01 | 2018-03-06 | Inovio Pharmaceuticals Inc | métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição. |
US11491342B2 (en) | 2015-07-01 | 2022-11-08 | Btl Medical Solutions A.S. | Magnetic stimulation methods and devices for therapeutic treatments |
US10695575B1 (en) | 2016-05-10 | 2020-06-30 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
US20180001107A1 (en) | 2016-07-01 | 2018-01-04 | Btl Holdings Limited | Aesthetic method of biological structure treatment by magnetic field |
US11266850B2 (en) | 2015-07-01 | 2022-03-08 | Btl Healthcare Technologies A.S. | High power time varying magnetic field therapy |
WO2017055522A1 (en) | 2015-09-29 | 2017-04-06 | Academisch Medisch Centrum | Stabilized env proteins of hiv |
US11253717B2 (en) | 2015-10-29 | 2022-02-22 | Btl Healthcare Technologies A.S. | Aesthetic method of biological structure treatment by magnetic field |
BR112018015893A2 (pt) | 2016-02-05 | 2019-03-06 | Inovio Pharmaceuticals Inc | vacinas de câncer e métodos de tratamento usando as mesmas |
MX2018011742A (es) | 2016-03-28 | 2019-02-14 | Ichor Medical Systems Inc | Metodo y aparato para suministro de agentes terapeuticos. |
JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
US11464993B2 (en) | 2016-05-03 | 2022-10-11 | Btl Healthcare Technologies A.S. | Device including RF source of energy and vacuum system |
US11247039B2 (en) | 2016-05-03 | 2022-02-15 | Btl Healthcare Technologies A.S. | Device including RF source of energy and vacuum system |
US11534619B2 (en) | 2016-05-10 | 2022-12-27 | Btl Medical Solutions A.S. | Aesthetic method of biological structure treatment by magnetic field |
US10583287B2 (en) | 2016-05-23 | 2020-03-10 | Btl Medical Technologies S.R.O. | Systems and methods for tissue treatment |
US10556122B1 (en) | 2016-07-01 | 2020-02-11 | Btl Medical Technologies S.R.O. | Aesthetic method of biological structure treatment by magnetic field |
JP7382230B2 (ja) | 2016-10-17 | 2023-11-16 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組み換えウイルスレプリコン系及びその使用 |
KR102655641B1 (ko) | 2016-12-05 | 2024-04-05 | 얀센 파마슈티칼즈, 인코포레이티드 | 유전자 발현을 향상시키기 위한 조성물 및 방법 |
WO2019042950A1 (en) | 2017-08-26 | 2019-03-07 | Academisch Medisch Centrum | IMPROVED HIV ENVELOPE GLYCOPROTETIC IMMUNOGENS |
BR112020010499A2 (pt) | 2017-12-13 | 2020-11-24 | Inovio Pharmaceuticals, Inc. | vacinas de câncer de alvo de mesotelina e usos das mesmas |
ES2938900T3 (es) | 2017-12-13 | 2023-04-17 | Inovio Pharmaceuticals Inc | Vacunas contra el cáncer dirigidas al PRAME y usos de las mismas |
US11235044B2 (en) | 2017-12-13 | 2022-02-01 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting MUC16 and uses thereof |
EA202091516A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
BR112020011976A2 (pt) | 2017-12-19 | 2020-11-24 | Janssen Sciences Ireland Unlimited Company | composição e kit imunogênicos contra o vírus da hepatite b, usos dos mesmos, e molécula de ácido nucleico de ocorrência não natural |
MA51312A (fr) | 2017-12-19 | 2020-10-28 | Bavarian Nordic As | Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb) |
EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
BR112020014525A2 (pt) | 2018-01-19 | 2020-12-08 | Janssen Pharmaceuticals, Inc. | Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes |
MX2021012225A (es) | 2019-04-11 | 2022-12-05 | Btl Medical Solutions A S | Metodos y aparatos para el tratamiento estetico de estructuras biologicas mediante radiofrecuencia y energia magnetica. |
WO2020255019A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative |
TW202114731A (zh) | 2019-06-18 | 2021-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | B型肝炎病毒(HBV)疫苗與靶向HBV之RNAi之組合 |
WO2020255039A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
WO2020255042A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative |
WO2020255035A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives |
WO2020254876A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Virus-like particle delivery of hepatitis b virus (hbv) vaccines |
US20220305116A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences lreland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives |
US20220305107A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
WO2020255010A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines |
WO2020255013A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives |
US20220324916A1 (en) | 2019-06-18 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Hepatitis B Virus (HBV) Vaccines and Uses Thereof |
US20220249647A1 (en) | 2019-06-18 | 2022-08-11 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
MA56523A (fr) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1 |
CA3140588A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor |
WO2020255022A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors |
CA3140702A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
CA3141003A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors |
WO2020255014A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Recombinant interleukin 12 construct and uses thereof |
EP3986460A2 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
WO2020255016A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
MA56534A (fr) | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) |
CA3143631A1 (en) | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines |
US11878167B2 (en) | 2020-05-04 | 2024-01-23 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
MX2022013485A (es) | 2020-05-04 | 2022-11-30 | Btl Healthcare Tech A S | Dispositivo y metodo para el tratamiento sin atencion del paciente. |
CA3181680A1 (en) | 2020-06-12 | 2021-12-16 | University Of Rochester | Encoding and expression of ace-trnas |
KR20230050328A (ko) | 2020-07-08 | 2023-04-14 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv에 대한 rna 레플리콘 백신 |
TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
WO2022146654A1 (en) | 2020-12-28 | 2022-07-07 | Janssen Pharmaceuticals, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
US11896816B2 (en) | 2021-11-03 | 2024-02-13 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
WO2023150753A1 (en) | 2022-02-07 | 2023-08-10 | University Of Rochester | Optimized sequences for enhanced trna expression or/and nonsense mutation suppression |
WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389069A (en) * | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
US5501662A (en) * | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
US5304120A (en) * | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
US5273525A (en) * | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5318514A (en) * | 1992-08-17 | 1994-06-07 | Btx, Inc. | Applicator for the electroporation of drugs and genes into surface cells |
US5468223A (en) * | 1992-11-30 | 1995-11-21 | C.N.R.S. Paris | Electrochemotherapy |
FR2703253B1 (fr) * | 1993-03-30 | 1995-06-23 | Centre Nat Rech Scient | Applicateur d'impulsions electriques pour traitement de tissus biologiques. |
US5993434A (en) * | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US5702359A (en) * | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
IL108775A (en) * | 1994-02-25 | 2003-09-17 | Univ Ramot | Method for efficient incorporation of molecules into cells |
EP0769151A1 (en) * | 1995-05-02 | 1997-04-23 | Koninklijke Philips Electronics N.V. | Method of and device for magnetic resonance imaging of objects |
US5944710A (en) * | 1996-06-24 | 1999-08-31 | Genetronics, Inc. | Electroporation-mediated intravascular delivery |
CA2294802A1 (fr) * | 1997-06-30 | 1999-01-14 | Michel Bureau | Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede |
-
1998
- 1998-04-03 CA CA002285056A patent/CA2285056C/en not_active Expired - Lifetime
- 1998-04-03 US US09/055,084 patent/US6110161A/en not_active Expired - Lifetime
- 1998-04-03 DK DK98909691T patent/DK1023107T3/da active
- 1998-04-03 WO PCT/IB1998/000487 patent/WO1998043702A2/en active IP Right Grant
- 1998-04-03 JP JP54134898A patent/JP2001520537A/ja active Pending
- 1998-04-03 ES ES98909691T patent/ES2273408T3/es not_active Expired - Lifetime
- 1998-04-03 KR KR10-1999-7009009A patent/KR100427786B1/ko not_active IP Right Cessation
- 1998-04-03 AT AT98909691T patent/ATE337794T1/de active
- 1998-04-03 EA EA199900882A patent/EA002087B1/ru not_active IP Right Cessation
- 1998-04-03 IL IL13210398A patent/IL132103A0/xx unknown
- 1998-04-03 CN CNB98803980XA patent/CN1198665C/zh not_active Expired - Lifetime
- 1998-04-03 EP EP98909691A patent/EP1023107B1/en not_active Expired - Lifetime
- 1998-04-03 DE DE69835761T patent/DE69835761T2/de not_active Expired - Lifetime
- 1998-04-03 NZ NZ337853A patent/NZ337853A/en not_active IP Right Cessation
- 1998-04-03 AU AU69906/98A patent/AU733628B2/en not_active Expired
-
1999
- 1999-10-04 NO NO19994820A patent/NO327806B1/no not_active IP Right Cessation
-
2005
- 2005-09-01 JP JP2005253462A patent/JP2006061701A/ja active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507984A (ja) * | 1997-06-30 | 2002-03-12 | ローヌ−プーラン・ロレ・エス・アー | 多細胞化真核生物細胞に核酸を導入する改良法およびその組合せ |
JP4664450B2 (ja) * | 1997-06-30 | 2011-04-06 | アンステイテユ・ギユスタブ・ルシー | 多細胞化真核生物細胞に核酸を導入する改良法およびその組合せ |
JP2009195756A (ja) * | 2002-04-05 | 2009-09-03 | Ichor Medical Systems Inc | 治療薬を送達する方法及び装置 |
JP2013099570A (ja) * | 2002-04-05 | 2013-05-23 | Ichor Medical Systems Inc | 治療薬を送達する方法及び装置 |
US9526836B2 (en) | 2002-04-05 | 2016-12-27 | Ichor Medical Systems, Inc. | Method and apparatus for delivery of therapeutic agents |
US10252004B2 (en) | 2002-04-05 | 2019-04-09 | Ichor Medical Systems, Inc. | Method and apparatus for delivery of therapeutic agents |
US9364664B2 (en) | 2004-03-08 | 2016-06-14 | Ichor Medical Systems, Inc. | Apparatus for electrically mediated delivery of therapeutic agents |
US9802035B2 (en) | 2004-03-08 | 2017-10-31 | Ichor Medical Systems, Inc. | Apparatus for electrically mediated delivery of therapeutic agents |
US10561834B2 (en) | 2004-03-08 | 2020-02-18 | Ichor Medical Systems, Inc. | Apparatus for electrically mediated delivery of therapeutic agents |
Also Published As
Publication number | Publication date |
---|---|
JP2006061701A (ja) | 2006-03-09 |
DE69835761T2 (de) | 2007-09-13 |
NO327806B1 (no) | 2009-09-28 |
CA2285056C (en) | 2004-12-14 |
CN1198665C (zh) | 2005-04-27 |
IL132103A0 (en) | 2001-03-19 |
US6110161A (en) | 2000-08-29 |
KR20010005932A (ko) | 2001-01-15 |
EP1023107B1 (en) | 2006-08-30 |
EA002087B1 (ru) | 2001-12-24 |
KR100427786B1 (ko) | 2004-04-30 |
ES2273408T3 (es) | 2007-05-01 |
AU6990698A (en) | 1998-10-22 |
DE69835761D1 (de) | 2006-10-12 |
AU733628B2 (en) | 2001-05-17 |
ATE337794T1 (de) | 2006-09-15 |
WO1998043702A2 (en) | 1998-10-08 |
NZ337853A (en) | 2002-03-28 |
CN1276740A (zh) | 2000-12-13 |
NO994820D0 (no) | 1999-10-04 |
EP1023107A1 (en) | 2000-08-02 |
CA2285056A1 (en) | 1998-10-08 |
NO994820L (no) | 1999-12-03 |
DK1023107T3 (da) | 2006-12-27 |
EA199900882A1 (ru) | 2001-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001520537A (ja) | 医薬品と核酸の骨格筋への導入方法 | |
US6261281B1 (en) | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells | |
McMahon et al. | Electroporation for gene transfer to skeletal muscles: current status | |
US7171264B1 (en) | Intradermal delivery of active agents by needle-free injection and electroporation | |
DE69826124T2 (de) | Verabreichung der nukleinsäure in den quergestreiften muskel | |
Jaroszeski et al. | In vivo gene delivery by electroporation | |
EP1648555B1 (en) | Method for introducing an Agent into a Cell | |
JP2003525912A (ja) | 遺伝子送達用核酸製剤および使用方法 | |
Rabussay et al. | Enhancement of therapeutic drug and DNA delivery into cells by electroporation | |
Jaroszeski et al. | Delivery of genes in vivo using pulsed electric fields | |
MXPA99009026A (en) | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle | |
Bui | Biphasic Gene Electrotransfer Enhances Gene Delivery in Vitro | |
Bigeya et al. | ELECTROTRANSFER/ELECTROPORATION FOR NON-VIRAL NUCLEIC ACID DELIVERY | |
JP2005524389A (ja) | 宿主組織内への核酸分子の電気的遺伝子導入の増強 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050601 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050901 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060425 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060816 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20060907 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20060914 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090421 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090723 |